CEO Ben‑Noon Shahar Buys 18,181 QTREX Shares, Reinforcing Confidence in Volatile Market

Insider Buying Continues Amid Volatile Market Conditions

Insider transactions at QTREX QUANTUM LTD reflect an ongoing commitment from executive leadership to align interests with minority shareholders. On October 9 2026, Ben‑Noon Dagi Shahar, the company’s chief executive officer, purchased 18,181 shares at $1.67 each, slightly above the closing price of $1.63. This transaction is part of a management share‑purchase plan announced in June and follows a series of significant buy‑side trades by Shahar over the previous months—most notably a 550,000‑share acquisition in late August and a 168,894‑share block in late September. Cumulatively, these purchases have elevated Shahar’s post‑transaction ownership to more than 3.6 million shares.

Implications for Investors and Company Outlook

The timing of Shahar’s latest purchase is significant. QTREX has recorded a sharp 104 % monthly rally, and its 52‑week high of $3.85 remains within reach. A CEO’s willingness to buy at current levels signals confidence in near‑term prospects, particularly as the company advances clinical trials for its respiratory support device. From a risk perspective, the company’s negative price‑earnings ratio and recent 53 % weekly gain highlight market volatility. Nonetheless, insider buying can serve as a counter‑balance to prevailing market sentiment, which remains dampened with a sentiment score of –22 and a buzz intensity of 60.53 %. While Shahar’s continued acquisitions may be perceived as a bullish signal, investors should consider the company’s yet unrealized profitability and the broader regulatory landscape affecting the healthcare sector.

Profile of Ben‑Noon Dagi Shahar

Shahar’s trading history demonstrates a pattern of strategic accumulation rather than opportunistic flipping. His first notable block in August involved a zero‑price purchase of 550,000 shares, a common exercise under the employee share‑option program. Subsequent acquisitions—168,894 shares in September at $0.71 each and 18,181 shares in October—show a willingness to pay above the market price when it aligns with a management plan. Over the last six months, Shahar has bought roughly 1.4 million shares, increasing his stake by about 20 %. The consistency of these trades suggests a long‑term commitment to the company’s mission rather than short‑term speculation.

Market Context and Forward‑Looking Signals

QTREX’s focus on healthcare and its pioneering respiratory technology positions the company at the intersection of clinical need and technological innovation. The recent price surge, coupled with a high 52‑week volatility range, indicates a window of opportunity for value investors. Shahar’s purchase, executed through an open‑market transaction under a management plan, may be interpreted as an endorsement of the company’s valuation trajectory. For investors, monitoring subsequent insider activity—particularly any potential sell‑side actions—will be essential in assessing whether leadership remains confident in the growth path or begins to hedge against upcoming regulatory or commercial milestones.